BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 14973075)

  • 1. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.
    Kulp SK; Yang YT; Hung CC; Chen KF; Lai JP; Tseng PH; Fowble JW; Ward PJ; Chen CS
    Cancer Res; 2004 Feb; 64(4):1444-51. PubMed ID: 14973075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
    Zhu J; Huang JW; Tseng PH; Yang YT; Fowble J; Shiau CW; Shaw YJ; Kulp SK; Chen CS
    Cancer Res; 2004 Jun; 64(12):4309-18. PubMed ID: 15205346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
    Hsu AL; Ching TT; Wang DS; Song X; Rangnekar VM; Chen CS
    J Biol Chem; 2000 Apr; 275(15):11397-403. PubMed ID: 10753955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms.
    Lin HP; Kulp SK; Tseng PH; Yang YT; Yang CC; Chen CS; Chen CS
    Mol Cancer Ther; 2004 Dec; 3(12):1671-80. PubMed ID: 15634661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.
    Ding H; Han C; Zhu J; Chen CS; D'Ambrosio SM
    Int J Cancer; 2005 Feb; 113(5):803-10. PubMed ID: 15499625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
    Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
    Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
    Levitt RJ; Pollak M
    Cancer Res; 2002 Dec; 62(24):7372-6. PubMed ID: 12499282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.
    Zhu J; Song X; Lin HP; Young DC; Yan S; Marquez VE; Chen CS
    J Natl Cancer Inst; 2002 Dec; 94(23):1745-57. PubMed ID: 12464646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
    Song X; Lin HP; Johnson AJ; Tseng PH; Yang YT; Kulp SK; Chen CS
    J Natl Cancer Inst; 2002 Apr; 94(8):585-91. PubMed ID: 11959891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
    Kern MA; Schubert D; Sahi D; Schöneweiss MM; Moll I; Haugg AM; Dienes HP; Breuhahn K; Schirmacher P
    Hepatology; 2002 Oct; 36(4 Pt 1):885-94. PubMed ID: 12297835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling.
    Yang HM; Kim HS; Park KW; You HJ; Jeon SI; Youn SW; Kim SH; Oh BH; Lee MM; Park YB; Walsh K
    Circulation; 2004 Jul; 110(3):301-8. PubMed ID: 15238462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3.
    Lai GH; Zhang Z; Sirica AE
    Mol Cancer Ther; 2003 Mar; 2(3):265-71. PubMed ID: 12657721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest.
    Han C; Leng J; Demetris AJ; Wu T
    Cancer Res; 2004 Feb; 64(4):1369-76. PubMed ID: 14973068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.
    Wun T; McKnight H; Tuscano JM
    Leuk Res; 2004 Feb; 28(2):179-90. PubMed ID: 14654083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
    Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
    Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib.
    Patti R; Gumired K; Reddanna P; Sutton LN; Phillips PC; Reddy CD
    Cancer Lett; 2002 Jun; 180(1):13-21. PubMed ID: 11911965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells.
    Wu T; Leng J; Han C; Demetris AJ
    Mol Cancer Ther; 2004 Mar; 3(3):299-307. PubMed ID: 15026550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.